Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)

Daniela Femminella, Grazia; Frangou, Eleni; Love, Sharon; Busza, Gail; Holmes, Clive; Ritchie, Craig; M. Lawrence, Robert; McFarlane, Brady; Tadros, George; H. Ridha, Basil; Bannister, Carol; Walker, Zuzana; Archer, Hilary; Coulthard, Elizabeth; R. Underwood, Benjamin; Prasanna, Aparna; Koranteng, Paul; Karim, Salman; Junaid, Kehinde; McGuinness, Bernadette; Nilforooshan, Ramin; Macharouthu, Ajay; Donaldson, Andrew; Thacker, Simon; Russell, Gregor; Malik, Naghma; Mate, Vandana; Knight, Lucy; Kshemendran, Sajeev; Harrison, John; J. Brooks, David; Peter Passmore, Anthony; Ballard, Clive; Edison, Paul

doi:10.1186/s13063-019-3259-x

Public

Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)

Published in Trials • Apr 3, 2019

Authors:

Grazia Daniela Femminella

Eleni Frangou

Sharon Love

Abstract

BACKGROUND: Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue currently approved for type 2 diabetes and obesity. Preclinical evidence in transgenic models of Alzheimer's disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plas...

Subject

Liraglutide

Medicine

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!